Treatment of Postoperative Crohn’s Disease

Authors:
  • PJPascal Juillerat
    Pascal Juillerat
  • CFChristian Felley
    Christian Felley
  • CMChristian Mottet
    Christian Mottet
  • JVJohn-Paul Vader
    John-Paul Vader
  • BBBernard Burnand
    Bernard Burnand
  • PMPierre Michetti
    Pierre Michetti
  • JGJean-Jacques Gonvers
    Jean-Jacques Gonvers

Abstract
At 1 year after a first resection, up to 80% of patients show an endoscopic recurrence, 10–20% have clinical relapse, and 5% have surgical recurrence. Smoking is one of the most important risk factors for postoperative recurrence. Preoperative disease activity and the severity of endoscopic lesions in the neoterminal ileum within the first postoperative year are predictors of symptomatic recurrence. Mesalamine is generally the first-line treatment used in the postoperative setting but still provokes considerable controversy as to its efficacy, in spite of the results of a meta-analysis. Immunosuppressive treatment (azathioprine, 6-MP) is based on scant evidence but is currently used as a second-line treatment in postsurgical patients at high risk for recurrence, with symptoms or with early endoscopic lesions in the neoterminal ileum. Nitroimidazole antibiotics (metronidazole, ornidazole) are also effective in the control of active Crohn’s disease in the postoperative setting. Given their known toxicity, they may be used as a third-line treatment as initial short-term prevention therapy rather than for long-term use. Conventional corticosteroids, budesonide or probiotics have no proven role in postoperative prophylaxis. Infliximab has not as yet been studied for use in the prevention of relapse after surgery.

This publication has 39 references indexed in Scilit: